The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone

Internal Medicine

Volumn 49, Issue 10, 2010, Pages 919-923

  Yamaguchi, Kohei ^a   Tsutsum, Etsuro ^a  

^a Kaiseikai Tsutsumi Hospital   (Japan)

Author keywords

Insulin sensitivity; Insulin therapy; Risperidone; Schizophrenia; Telmisartan

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BRONAZEPAM; CANDESARTAN; CLONAZEPAM; FELODIPINE; FLUINDOSTATIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; ISOPHANE INSULIN; LEVOMEPROMAZINE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIPERIDINE; RISPERIDONE; TELMISARTAN; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SELF MONITORING; SIDE EFFECT; WEIGHT REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TETRAZOLES;

EID: 77952930674     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3107     Document Type: Article

References (24)

1. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan. Diabetes Care 27: 1015, 2004.
2. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 28: 498, 2005.
3. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25: 841-848, 2007.
4. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337-345, 2002.
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596-601, 2004.
6. Ebehard J, Lindström E, Holstad M, Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 115: 268-276, 2007.
7. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559,2008.
8. Derosa G, Cicero AFG, D'Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor- α. Hypertens Res 29: 849-856, 2006.
9. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32: 261- 268,2007.
10. Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 24: 146-153, 2007.
11. Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism 57: 1473-1478, 2009.
12. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48: 51-57, 2006.
13. Zanchi A, Dulloo AG, Perregaux C, Montani J-P, Burnier M. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab 293: E91-E95, 2007.
14. Sugimoto K, Qi NR, Kazdová L, Pravence M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009, 2006.
15. Sharm AM. The obese patients with diabetes mellitus: From re-search targets to treatment options. Amer J Med 119(5 Suppl 1): S17-S23, 2006.
16. Viljanen APM, Iozzo P, Borra R, et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab 94: 50-55, 2009.
17. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 29: 957-961, 2006.
18. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 46: 1331-1336, 2007.
19. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. Hypertension 43:993-1002, 2004.
20. Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77: 210-214, 2007.
21. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin Type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109: 2054-2057, 2004.
22. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87: 2918-2923, 2002.
23. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 68: 1733-1740, 2007.
24. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes. Biol Psychiatry 50: 148-149, 2001.